Breaking News Instant updates and real-time market news.

IONS

Ionis Pharmaceuticals

$62.98

-0.01 (-0.02%)

04:55
07/26/19
07/26
04:55
07/26/19
04:55

Ionis Pharmaceuticals management to meet with Needham

Meetings to be held in Minneapolis, MN on July 25 in Kansas City, MO on July 26 hosted by Needham.

  • 26

    Jul

  • 09

    Sep

IONS Ionis Pharmaceuticals
$62.98

-0.01 (-0.02%)

05/07/19
MSCO
05/07/19
NO CHANGE
MSCO
Biogen could rise, or fall, 5% based on Zolgensma label, says Morgan Stanley
Morgan Stanley analyst Matthew Harrison noted that Novartis' (NVS) gene therapy for the rare disease spinal muscular atrophy, Zolgensma, is expected to be approved by the FDA this month. He also noted that Biogen's (BIIB) Spinraza is currently the only approved drug for SMA and represents 17% of Biogen's estimated 2019 sales. The public data for Novartis' Zolgensma are only in type 1 patients, or infants, said Harrison, who sees three potential scenarios for the drug's label. In the first, which would involve broad approval across the three patient classes of infants, children and adults, Harrison thinks Novartis shares could be up 1-2%, Biogen could fall about 5%, Ionis (IONS), which receives royalties from Biogen, could be down about 10%, and Regenxbio (RGNX), which will receive royalties from Novartis, could be up 10-15% or more. In the second case, where Zolgensma is granted a Type 1 approval with no restriction, Harrison sees Novartis unchanged, Biogen down 1-3%, Ionis falling 3-5% and Regenxbio rising 5%. In the third scenario, where Zolgensma gets a Type 1 approval but with a weight/age restriction, the analyst thinks Novartis would be down 1-2%, Biogen would be up 2-3%, Ionis could rise 5% and Regenxbio could fall 5-10%. Harrison's base case assumption is that Zolgensma will ultimately capture the majority market share in type 1 patients and a "significant portion" of type 2, or pediatric, patients.
05/09/19
PIPR
05/09/19
NO CHANGE
Target $75
PIPR
Neutral
Ionis Pharmaceuticals shares 'more interesting on pullback', says Piper Jaffray
Piper Jaffray analyst Tyler Van Buren kept his Neutral rating and $75 price target on Ionis Pharmaceuticals after its Q1 results with Spinraza royalties and Tegsedi sales seen "in line with expectations". The analyst believes that the company's pipeline is maturing as it gets ready to launch Waylivra in Europe next quarter and also sees its Huntington's OLE continuing to progress. Van Buren contends that Ionis Pharmaceuticals stock is "becoming more interesting" from a long term investment perspective given the recent pullback in price.
05/24/19
PIPR
05/24/19
NO CHANGE
Target $75
PIPR
Neutral
Piper 'incrementally more positive' on Ionis after management meetings
Piper Jaffray analyst Tyler Van Buren says he's "incrementally more positive" on shares of Ionis Pharmaceuticals after hosting meetings with management. The company is in a "healthy and very rare" financial position relative to other mid-cap biotechs with ongoing profitability, $2.3B in cash, and nearly $400M in "durable" annual research and development revenues that offset R&D expenses, Van Buren tells investors in a research note. This provides Ionis valuation support, long-term stability, and allows for value creation on a "step-function basis" as each additional clinical asset becomes de-risked, adds the analyst. Van Buren keeps a Neutral rating on the shares with a $75 price target.
07/23/19
JPMS
07/23/19
NO CHANGE
JPMS
Neutral
Competition questions for Biogen, Ions' Spinraza not dissipating soon, says JPMorgan
Following Biogen's (BIIB) quarterly results, JPMorgan analyst Jessica Fye notes that while there seems to be limited second quarter impact to the company's and partner Ions Pharmaceuticals' (IONS) Spinraza from Novartis' (NVS) Zolgensma international revenues were down quarter over quarter for a variety of reasons despite double-digit patient growth. Overall, the analyst maintains her view that Roche (RHHBY) and PTC Therapeutics' (PTCT) Risdiplam represents a key potential competitive threat to Spinraza given the convenience of oral dosing and with filing for Risdiplam anticipated in the second half of 2019, in addition to Zolgensma's launch, Fye does not see questions related to competition for Spinraza dissipating anytime soon. The analyst reiterates a Neutral rating on Ions Pharmaceuticals' shares.

TODAY'S FREE FLY STORIES

STX

Seagate

$56.92

0.88 (1.57%)

13:35
09/18/19
09/18
13:35
09/18/19
13:35
Options
Seagate put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

NLSN

Nielsen

$22.45

-0.13 (-0.58%)

13:34
09/18/19
09/18
13:34
09/18/19
13:34
Periodicals
Nielsen acquires minority stake in brand-safety company Open Slate, WSJ reports »

Nielsen Holdings has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BX

Blackstone

$52.93

-0.57 (-1.07%)

13:30
09/18/19
09/18
13:30
09/18/19
13:30
Periodicals
Blackstone near $2.9B deal to buy Great Wolf Resorts, Bloomberg says »

Privately held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Sep

  • 26

    Sep

RUBI

Rubicon Project

$9.36

-0.05 (-0.53%)

, TLRA

Telaria

$8.03

-0.195 (-2.37%)

13:26
09/18/19
09/18
13:26
09/18/19
13:26
Recommendations
Rubicon Project, Telaria, Trade Desk analyst commentary  »

Google auction shift…

RUBI

Rubicon Project

$9.36

-0.05 (-0.53%)

TLRA

Telaria

$8.03

-0.195 (-2.37%)

TTD

Trade Desk

$209.29

-3.72 (-1.75%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

  • 24

    Sep

  • 25

    Sep

  • 26

    Sep

  • 30

    Sep

  • 07

    Nov

  • 12

    Nov

FDX

FedEx

$149.76

-23.77 (-13.70%)

13:25
09/18/19
09/18
13:25
09/18/19
13:25
Downgrade
FedEx rating change  »

FedEx downgraded to Hold…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 30

    Sep

  • 01

    Oct

  • 13

    Nov

  • 17

    Dec

13:25
09/18/19
09/18
13:25
09/18/19
13:25
Conference/Events
The SEC to hold a meeting to hear oral arguments »

The Commission will hear…

SOLO

ElectraMeccanica

$2.40

0.04 (1.69%)

13:24
09/18/19
09/18
13:24
09/18/19
13:24
Initiation
ElectraMeccanica initiated  »

ElectraMeccanica…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UN

Unilever; also tag UL

$60.45

0.01 (0.02%)

, PG

Procter & Gamble

$121.47

0.32 (0.26%)

13:23
09/18/19
09/18
13:23
09/18/19
13:23
Recommendations
Unilever; also tag UL, Procter & Gamble, Unilever; also tag UN, Reckitt Benckiser, Henkel, L'Oreal analyst commentary  »

EU Household &…

UN

Unilever; also tag UL

$60.45

0.01 (0.02%)

PG

Procter & Gamble

$121.47

0.32 (0.26%)

UL

Unilever; also tag UN

$61.51

0.05 (0.08%)

RBGLY

Reckitt Benckiser

$0.00

(0.00%)

HENKY

Henkel

$0.00

(0.00%)

LRLCY

L'Oreal

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Oct

  • 08

    Oct

  • 18

    Oct

  • 12

    Nov

NRC

National Research Corporation

$63.59

1.59 (2.56%)

13:23
09/18/19
09/18
13:23
09/18/19
13:23
Hot Stocks
National Research Corporation director Donald Berwick sold over $433K in shares »

National Research…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$188.14

0.01 (0.01%)

, TWTR

Twitter

$42.66

-0.59 (-1.36%)

13:22
09/18/19
09/18
13:22
09/18/19
13:22
On The Fly
#SocialStocks: Facebook clarifies oversight structure, Snap in talks to add news »

Welcome to…

FB

Facebook

$188.14

0.01 (0.01%)

TWTR

Twitter

$42.66

-0.59 (-1.36%)

SNAP

Snap

$16.77

-0.1 (-0.59%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Sep

  • 18

    Sep

  • 20

    Sep

  • 24

    Sep

  • 27

    Oct

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

13:17
09/18/19
09/18
13:17
09/18/19
13:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

13:16
09/18/19
09/18
13:16
09/18/19
13:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TYL

Tyler Technologies

$259.19

-0.47 (-0.18%)

13:15
09/18/19
09/18
13:15
09/18/19
13:15
Conference/Events
Tyler Technologies management to meet with Needham »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Sep

  • 25

    Sep

  • 26

    Sep

BRKR

Bruker

$43.21

0.34 (0.79%)

13:14
09/18/19
09/18
13:14
09/18/19
13:14
Conference/Events
Bruker management to meet with Needham »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 24

    Sep

RST

Rosetta Stone

$18.99

-0.22 (-1.15%)

13:13
09/18/19
09/18
13:13
09/18/19
13:13
Conference/Events
Rosetta Stone management to meet with Needham »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

  • 25

    Sep

CYRX

Cryoport

$17.92

0.17 (0.96%)

13:07
09/18/19
09/18
13:07
09/18/19
13:07
Hot Stocks
Breaking Hot Stocks news story on Cryoport »

Cryoport CEO says Seeking…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CYRX

Cryoport

$17.92

0.17 (0.96%)

, GILD

Gilead

$65.78

-0.39 (-0.59%)

13:05
09/18/19
09/18
13:05
09/18/19
13:05
On The Fly
Meet Cryoport: A Fly exclusive interview with CEO Jerry Shelton »

In an exclusive interview…

CYRX

Cryoport

$17.92

0.17 (0.96%)

GILD

Gilead

$65.78

-0.39 (-0.59%)

NVS

Novartis

$86.46

-0.11 (-0.13%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Sep

  • 18

    Sep

  • 19

    Sep

  • 23

    Sep

  • 24

    Sep

  • 25

    Sep

  • 27

    Sep

CYRX

Cryoport

$17.92

0.17 (0.96%)

13:04
09/18/19
09/18
13:04
09/18/19
13:04
Hot Stocks
Breaking Hot Stocks news story on Cryoport »

Shelton sees Cryoport…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CYRX

Cryoport

$17.92

0.17 (0.96%)

13:04
09/18/19
09/18
13:04
09/18/19
13:04
Hot Stocks
Breaking Hot Stocks news story on Cryoport »

Cryoport, Vineti…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CYRX

Cryoport

$17.92

0.17 (0.96%)

, GILD

Gilead

$65.80

-0.37 (-0.56%)

13:04
09/18/19
09/18
13:04
09/18/19
13:04
Hot Stocks
Breaking Hot Stocks news story on Cryoport, Gilead, Novartis »

Gilead, Novartis…

CYRX

Cryoport

$17.92

0.17 (0.96%)

GILD

Gilead

$65.80

-0.37 (-0.56%)

NVS

Novartis

$86.46

-0.11 (-0.13%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Sep

  • 18

    Sep

  • 19

    Sep

  • 23

    Sep

  • 24

    Sep

  • 25

    Sep

  • 27

    Sep

AEGN

Aegion

$20.77

-0.46 (-2.17%)

13:03
09/18/19
09/18
13:03
09/18/19
13:03
Hot Stocks
Aegion unit awarded $9.3M contract from MWRD in Denver »

Aegion announced that its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Sep

BYND

Beyond Meat

$157.51

-2.86 (-1.78%)

, QSR

Restaurant Brands

$73.77

-0.08 (-0.11%)

13:01
09/18/19
09/18
13:01
09/18/19
13:01
Periodicals
Tim Hortons to pull back on Beyond Meat offerings, Journal de Montreal says »

A translation of a French…

BYND

Beyond Meat

$157.51

-2.86 (-1.78%)

QSR

Restaurant Brands

$73.77

-0.08 (-0.11%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

BX

Blackstone

$52.97

-0.53 (-0.99%)

13:01
09/18/19
09/18
13:01
09/18/19
13:01
Periodicals
Breaking Periodicals news story on Blackstone »

Blackstone near $2.9B…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Sep

  • 26

    Sep

RYAAY

Ryanair

$61.95

-0.14 (-0.23%)

12:53
09/18/19
09/18
12:53
09/18/19
12:53
Initiation
Ryanair initiated  »

Ryanair initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$300.17

-0.77 (-0.26%)

12:47
09/18/19
09/18
12:47
09/18/19
12:47
Hot Stocks
Gundlach sees 'increasing probability' of recession before 2020 election »

Jeffrey Gundlach of…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$300.17

-0.77 (-0.26%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.